Literature DB >> 28606739

Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Julia Y Ljubimova1, Tao Sun2, Leila Mashouf3, Alexander V Ljubimov4, Liron L Israel2, Vladimir A Ljubimov5, Vida Falahatian6, Eggehard Holler7.   

Abstract

Nanomedicine is a rapidly evolving form of therapy that holds a great promise for superior drug delivery efficiency and therapeutic efficacy than conventional cancer treatment. In this review, we attempt to cover the benefits and the limitations of current nanomedicines with special attention to covalent nano conjugates for imaging and drug delivery in the brain. The improvement in brain tumor treatment remains dismal despite decades of efforts in drug development and patient care. One of the major obstacles in brain cancer treatment is the poor drug delivery efficiency owing to the unique blood-brain barrier (BBB) in the CNS. Although various anti-cancer agents are available to treat tumors outside of the CNS, the majority fails to cross the BBB. In this regard, nanomedicines have increasingly drawn attention due to their multi-functionality and versatility. Nano drugs can penetrate BBB and other biological barriers, and selectively accumulate in tumor cells, while concurrently decreasing systemic toxicity.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood-brain-barrier (BBB); Brain cancer; Covalent nano conjugates; Drug delivery; Nanomedicine for brain imaging

Mesh:

Substances:

Year:  2017        PMID: 28606739      PMCID: PMC5578712          DOI: 10.1016/j.addr.2017.06.002

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  234 in total

Review 1.  Molecular pathogenesis of Bacillus anthracis infection.

Authors:  S F Little; B E Ivins
Journal:  Microbes Infect       Date:  1999-02       Impact factor: 2.700

Review 2.  Morpholino antisense oligomers: the case for an RNase H-independent structural type.

Authors:  J Summerton
Journal:  Biochim Biophys Acta       Date:  1999-12-10

3.  Synthetic substrates and inhibitors of beta-poly(L-malate)-hydrolase (polymalatase).

Authors:  B Gasslmaier; C M Krell; D Seebach; E Holler
Journal:  Eur J Biochem       Date:  2000-08

4.  Isolation of poly(beta-L-malic acid)-degrading bacteria and purification and characterization of the PMA hydrolase from Comamonas acidovorans strain 7789.

Authors:  C Gödde; M Liebergesell; A Steinbüchel
Journal:  FEMS Microbiol Lett       Date:  1999-04-15       Impact factor: 2.742

Review 5.  Glutamyl hydrolase. pharmacological role and enzymatic characterization.

Authors:  J Galivan; T J Ryan; K Chave; M Rhee; R Yao; D Yin
Journal:  Pharmacol Ther       Date:  2000-03       Impact factor: 12.310

Review 6.  HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action.

Authors:  J Kopecek; P Kopecková; T Minko; Z Lu
Journal:  Eur J Pharm Biopharm       Date:  2000-07       Impact factor: 5.571

7.  Role of extracellular matrix assembly in interstitial transport in solid tumors.

Authors:  P A Netti; D A Berk; M A Swartz; A J Grodzinsky; R K Jain
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

8.  DNA delivery systems based on complexes of DNA with synthetic polycations and their copolymers.

Authors:  D Oupický; C Konák; K Ulbrich; M A Wolfert; L W Seymour
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

9.  Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery.

Authors:  A Krol; J Maresca; M W Dewhirst; F Yuan
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

10.  Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.

Authors:  Y Zou; Q P Wu; W Tansey; D Chow; M C Hung; C Charnsangavej; S Wallace; C Li
Journal:  Int J Oncol       Date:  2001-02       Impact factor: 5.650

View more
  18 in total

1.  Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme.

Authors:  Rameshwar Patil; Anna Galstyan; Tao Sun; Ekaterina S Shatalova; Pramod Butte; Adam N Mamelak; Christine Carico; David S Kittle; Zachary B Grodzinski; Antonella Chiechi; Hui Ding; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Biomaterials       Date:  2019-03-23       Impact factor: 12.479

Review 2.  Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain.

Authors:  Liron L Israel; Anna Galstyan; Eggehard Holler; Julia Y Ljubimova
Journal:  J Control Release       Date:  2020-01-07       Impact factor: 9.776

3.  A mitochondria-targeting lipid-small molecule hybrid nanoparticle for imaging and therapy in an orthotopic glioma model.

Authors:  Menghuan Tang; Kai Lin; Mythili Ramachandran; Longmeng Li; Hongye Zou; Huzhi Zheng; Zhao Ma; Yuanpei Li
Journal:  Acta Pharm Sin B       Date:  2022-04-14       Impact factor: 14.903

4.  Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells.

Authors:  Andrei A Kramerov; Ruchi Shah; Hui Ding; Eggehard Holler; Sue Turjman; Yaron S Rabinowitz; Sean Ghiam; Ezra Maguen; Clive N Svendsen; Mehrnoosh Saghizadeh; Julia Y Ljubimova; Alexander V Ljubimov
Journal:  Nanomedicine       Date:  2020-11-10       Impact factor: 5.307

Review 5.  Gene Therapy in the Anterior Eye Segment.

Authors:  Cynthia Amador; Ruchi Shah; Sean Ghiam; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.391

6.  Single- and Multi-Arm Gadolinium MRI Contrast Agents for Targeted Imaging of Glioblastoma.

Authors:  Rameshwar Patil; Anna Galstyan; Zachary B Grodzinski; Ekaterina S Shatalova; Shawn Wagner; Liron L Israel; Hui Ding; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Int J Nanomedicine       Date:  2020-05-01

7.  Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.

Authors:  Anna Galstyan; Janet L Markman; Ekaterina S Shatalova; Antonella Chiechi; Alan J Korman; Rameshwar Patil; Dmytro Klymyshyn; Warren G Tourtellotte; Liron L Israel; Oliver Braubach; Vladimir A Ljubimov; Leila A Mashouf; Arshia Ramesh; Zachary B Grodzinski; Manuel L Penichet; Keith L Black; Eggehard Holler; Tao Sun; Hui Ding; Alexander V Ljubimov; Julia Y Ljubimova
Journal:  Nat Commun       Date:  2019-08-28       Impact factor: 14.919

8.  Noninvasive Brain Tumor Imaging Using Red Emissive Carbonized Polymer Dots across the Blood-Brain Barrier.

Authors:  Yang Liu; Junjun Liu; Jiayi Zhang; Xiucun Li; Fangsiyu Lin; Nan Zhou; Bai Yang; Laijin Lu
Journal:  ACS Omega       Date:  2018-07-16

Review 9.  Nanodrug Delivery Systems for the Treatment of Ovarian Cancer.

Authors:  Jonathan M Pantshwa; Pierre P D Kondiah; Yahya E Choonara; Thashree Marimuthu; Viness Pillay
Journal:  Cancers (Basel)       Date:  2020-01-15       Impact factor: 6.639

10.  Synergetic therapy of glioma mediated by a dual delivery system loading α-mangostin and doxorubicin through cell cycle arrest and apoptotic pathways.

Authors:  Wen Nie; Xin Zan; Ting Yu; Mengni Ran; Zehua Hong; Yihong He; Tingting Yang; Yan Ju; Xiang Gao
Journal:  Cell Death Dis       Date:  2020-10-28       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.